| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/17/2001 | US6262040 Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) |
| 07/17/2001 | US6262026 Chimeric proteins for use in transport of a selected substance into cells |
| 07/17/2001 | US6261840 Nucleotide sequences for gene expression inhibition of protein phosphatase 1b, a protein tyrosine phosphatase; diagnosis and antisense therapy of related diseases |
| 07/17/2001 | US6261606 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 07/17/2001 | US6261572 In situ administering |
| 07/17/2001 | US6261544 Poly(hydroxy acid)/polymer conjugates for skin applications |
| 07/17/2001 | CA2160961C New tricyclic amide compounds, process for preparing the same and pharmaceutical compositions containing them |
| 07/12/2001 | WO2001049838A2 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 07/12/2001 | WO2001049740A1 Novel fgf homolog zfgf12 |
| 07/12/2001 | WO2001049684A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/12/2001 | WO2001049674A2 Glycosidase inhibitors and preparation thereof |
| 07/12/2001 | WO2001049673A2 Compounds and methods for modulation of estrogen receptors |
| 07/12/2001 | WO2001049670A1 5,10-dihydroacridines as calcium channel blockers |
| 07/12/2001 | WO2001049312A2 O-superfamily conotoxin peptides |
| 07/12/2001 | WO2001049307A1 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses |
| 07/12/2001 | WO2001049305A2 Process for obtaining thylakoids from plants, pure thylakoids and use thereof |
| 07/12/2001 | WO2001049295A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | WO2001049287A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/12/2001 | WO2001049280A2 Weight promoting composition, method, and product |
| 07/12/2001 | WO2001049261A2 Stable aqueous deoxyfructosazine solution |
| 07/12/2001 | WO2001044485A8 Conjugated fatty acids and related compounds, and method for their enzymatic preparation |
| 07/12/2001 | WO2001021604A8 Substituted piperazine derivatives, the production thereof and their use as inhibitors of the microsomal triglyceride-transfer protein (mtp) |
| 07/12/2001 | WO2001004113A3 Process for the preparation of paroxetine and synthetic intermeditates thereof |
| 07/12/2001 | WO2001000220A3 Lipoprotein lipase (lpl) variant therapeutics |
| 07/12/2001 | WO2000078697A3 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 07/12/2001 | WO2000074724A3 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 07/12/2001 | WO2000074722A3 Modification of biological elements |
| 07/12/2001 | WO2000064921A3 Process of purifying phytosterols from wood or plant-derived sources by means of metal salt complexes and compositions resulting therefrom |
| 07/12/2001 | WO2000063361A3 A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| 07/12/2001 | WO2000055318A8 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 07/12/2001 | WO2000041528A9 Improved controlled release compositions and method |
| 07/12/2001 | WO2000005223A3 Heterocyclic derivatives and their use as integrin inhibitors |
| 07/12/2001 | US20010007875 Antidiabetic agents |
| 07/12/2001 | US20010007853 By inhalation |
| 07/12/2001 | US20010007755 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| 07/12/2001 | US20010007693 Food products having enhanced cocoa polyphenol content and processes for producing the same |
| 07/12/2001 | US20010007670 Novel formulations comprising lipid-regulating agents |
| 07/12/2001 | US20010007656 Introducing cells treated in vivo with DNA segment comprising transcription factor gene (c-Myc) and operably linked promoter sequence to patient |
| 07/12/2001 | DE19963179A1 Substituierte 1- und 2-Naphthol-Mannichbasen Substituted 1- and 2-naphthol Mannich bases |
| 07/12/2001 | DE19963175A1 Verwendung von substituierten 4-Amino-1-phenylbutan-2-ol-Verbindungen als Arzneimittel Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 07/12/2001 | DE19963174A1 Substituierte Pyrrol-Mannichbasen Substituted pyrrole Mannich bases |
| 07/12/2001 | DE19962470A1 Verwendung von Chemotherapeutika Use of chemotherapeutic agents |
| 07/12/2001 | CA2396688A1 Glycosidase inhibitors and methods of synthesizing same |
| 07/12/2001 | CA2396529A1 O-superfamily conotoxin peptides |
| 07/12/2001 | CA2396401A1 Novel fgf homolog zfgf12 |
| 07/12/2001 | CA2396393A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | CA2396059A1 Compounds and methods for modulation of estrogen receptors |
| 07/12/2001 | CA2395695A1 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses |
| 07/12/2001 | CA2394199A1 5,10-dihydroacridines as calcium channel blockers |
| 07/12/2001 | CA2330465A1 Process for increasing egg production and strenghtening poultry egg shell |
| 07/11/2001 | EP1114646A2 System and method for providing a sterile medical solution containing glucose or glucose-like compounds |
| 07/11/2001 | EP1114645A2 System and method for providing a sterile medical solution containing glucose or glucose-like compounds |
| 07/11/2001 | EP1114644A1 Composition comprising NPH insulin (neutral protamine hagedorn insulin) |
| 07/11/2001 | EP1114159A1 Methods and compositions relating to egf-repeat-containing polypeptides |
| 07/11/2001 | EP1114158A2 Human cytoskeleton associated proteins |
| 07/11/2001 | EP1114155A2 Human gpcr proteins |
| 07/11/2001 | EP1114146A2 Human serine/threonine protein kinases |
| 07/11/2001 | EP1114053A1 Pyrrolopyrimidines as protein kinase inhibitors |
| 07/11/2001 | EP1114052A1 4-aminopyrrolopyrimidines as kinase inhibitors |
| 07/11/2001 | EP1114051A1 INHIBITORS OF p38 |
| 07/11/2001 | EP1114040A1 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| 07/11/2001 | EP1114037A1 Benzoxazine and benzothiazine derivatives and their use in medicines |
| 07/11/2001 | EP1114033A1 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114032A1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114031A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1113801A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 07/11/2001 | EP1113799A1 Protein formulations |
| 07/11/2001 | EP1113791A2 Bioflavonoid as blood glucose level lowering agent |
| 07/11/2001 | EP1113790A1 Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases |
| 07/11/2001 | EP1113726A1 Composition containing neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-related diseases |
| 07/11/2001 | EP1113724A1 Composition containing natural phenolic compounds for preventing or treating elevated blood lipid level-related diseases |
| 07/11/2001 | EP0969865A4 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| 07/11/2001 | EP0760676B1 Materials and methods for treatment of plaquing diseases |
| 07/11/2001 | CN1303429A Therapeutic applications of mature FLINT (mFLINT) polypeptides or OPG3, member of TNF receptor superfamily |
| 07/11/2001 | CN1303381A Dipeptidyl peptidase IV effectors |
| 07/11/2001 | CN1303379A 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 07/11/2001 | CN1303364A Aminocyclohexyl ether compounds and uses thereof |
| 07/11/2001 | CN1303298A Gene therapy approaches to supply apolipoprotein A-1 agonists and their use to treat dyslipidemic disorders |
| 07/11/2001 | CN1303281A Use of compounds for elevation of pyruvate dehydrogenase activity |
| 07/11/2001 | CN1302800A Method for preparing 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline |
| 07/11/2001 | CN1302793A Zinc L-threonate, its preparing process and its application as zinc-supplementing agent |
| 07/11/2001 | CN1302658A Hypolipemic Xiancao tea and its preparing process |
| 07/11/2001 | CN1302646A Exterior-applied ointment for lossing weight and its preparing process |
| 07/11/2001 | CN1302643A Prescription for treating diabetes |
| 07/11/2001 | CN1302631A 'Zhanbikang' capsule |
| 07/11/2001 | CN1302629A Buccal lozenge of notoginseng flower |
| 07/11/2001 | CN1302618A Process for preparing medicine to treat diabetes |
| 07/11/2001 | CN1302559A Curcumin preparation |
| 07/11/2001 | CN1068318C 2-Substituted 1,2,5-thiadiazolidin-3-onel, 1-dioxides and compositions and method of use thereof |
| 07/11/2001 | CA2331012A1 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| 07/10/2001 | US6258953 Arylacrylamide derivatives |
| 07/10/2001 | US6258850 3-aryl-2-hydroxypropionic acid derivative (I) |
| 07/10/2001 | US6258846 Enriching breast milk |
| 07/10/2001 | US6258834 Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives |
| 07/10/2001 | US6258833 Enzyme inhibitors and antiinflammatory agents |
| 07/10/2001 | US6258832 Reduction of compounds with aluminum in aprotic solvent |
| 07/10/2001 | US6258826 Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
| 07/10/2001 | US6258817 Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof |
| 07/10/2001 | US6258804 Triazepinones, process for their preparation and their therapeutic application |
| 07/10/2001 | US6258790 Antisense modulation of integrin α4 expression |